AMAshesha Mechineni

Ashesha Mechineni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ashesha Mechineni has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Philips Respironics Recalled CPAP/BPAP Masks

    by Sonal Malhotra, Mohammed Alzoubaidi, Ashesha Mechineni


  • Open Access

    Use of Systemic Anticoagulation in COVID-19: Delving Beyond Theoretical Hypothesis

    by Christopher Millet, Spandana Narvaneni, Fady Shafeek, Sherif Roman, Ashesha Mechineni, Rajapriya Manickam

    Studies suggest that COVID-19 infection may induce increased hypercoagulability, leading to thrombotic complications. The high rates of thrombotic complications among patients receiving standard-dose deep venous thrombosis (DVT) prophylaxis have prompted some clinicians to support the empiric increase of anticoagulation (AC) doses used for prophylaxis in patients with COVID-19. At present, the optimal anticoagulant agents, dosages, and duration have not been designated. We conducted a retrospective study to assess for outcomes in patients who received treatment for COVID-19 based on various dosings of AC. This was a single-institution, retrospective cross-sectional study including patients with a positive COVID-19 test who were admitted within the St. Joseph’s Health Network from September to November of 2020. The inclusion criteria were men and women aged 18 years or older who had confirmed COVID-19 by polymerase chain reaction (PCR). Medical charts of patients who met the inclusion criteria were audited to obtain information. The patients were separated into three cohorts: those who received DVT prophylactic dose of AC, those who received an intermediate dose of AC, and those who received therapeutic AC. A total of 440 patients were included in the study, of whom 236 were Hispanic (50.3%), 131 were Caucasian (27.1%), 47 were African American (10.7%), and 26 were Asian (5.9%). The most common comorbidities were hypertension (273/440 [62.2%]), diabetes 189/440 [43.1%]), and coronary artery disease (60/440 [13.7%]). In the DVT prophylactic dose of AC cohort, there were 215 patients, and the average length of stay was 10.3 days. Eleven patients experienced bleeding events, five patients experienced thrombotic events, 16 patients required mechanical ventilation, and 20 patients died. In the intermediate dose of AC cohort, there were 63 patients, and the average length of stay was 10.3 days. Three patients experienced bleeding events, two patients experienced thrombotic events, seven patients required mechanical invasive ventilation, and 11 patients died. In the therapeutic dose of AC cohort, there were 162 patients, and the average length of stay was 14 days. In this cohort, 19 patients experienced bleeding events, 12 patients experienced thrombotic events, 26 patients required invasive mechanical ventilation, and 29 patients died. Patients who received intermediate dosing of AC also had the lowest risk of thrombotic events (0.05). Patients who received intermediate dosing of AC had the lowest rates of requiring both high-flow nasal cannula (p = 0.0001) and invasive mechanical ventilation (p = 0.031). Patients who received intermediate dosing of AC had a lower rate of bleeding compared to those who received the DVT prophylaxis dose and systemic AC dose (p = 0.037). The DVT prophylactic and intermediate dosing of AC groups had a shorter length of stay in comparison to the systemic AC group (p = 0.0002). In comparison to the venous thromboembolism prophylaxis dose and systemic AC dose groups, intermediate dosing of AC had the lowest rates of hemorrhage, mortality, length of stay, and requirement of high-flow nasal cannula or mechanical invasive ventilation. In the systemic dose AC group, there were worse clinical outcomes in terms of length of stay, incidence of bleeding events, requirement of mechanical ventilator use, and rate of mortality.


  • Open Access

    Pulmonary Sclerosing Pneumocytoma: An Essential Differential Diagnosis for a Lung Nodule

    by Rajapriya Manickam, Ashesha Mechineni

    Pulmonary sclerosing pneumocytoma, previously known as pulmonary sclerosing hemangioma, is a rare benign lung tumor with a low prevalence. We present this condition in a 26-year-old, young, non-smoking female with a slow-growing pulmonary nodule incidentally noted on imaging. Serial computed tomography(CT) scans revealed slow growth, and invasive testing was recommended. The patient underwent a left lateral thoracotomy and based on frozen section findings. A left lower lobectomy was performed. The final pathological diagnosis revealed sclerosing pneumocytoma. This is an atypical patient demographic considering the propensity of the disease for middle-aged Asian women. The case presentation and work-up highlight this critical differential diagnosis for incidental pulmonary nodules increasingly being noted due to widespread use of imaging for screening and routine care in the current medical climate. There are no specific imaging criteria to diagnose this condition. The final diagnosis is made only after surgical biopsy and histopathology. No additional treatment is needed following the diagnosis.


  • Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness

    by Ashesha Mechineni, Hagar Kassab, Rajapriya Manickam

    Remdesivir is a nucleoside analog, which inhibits viral RNA replication by blocking RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic, repurposed, and gained promin...


  • Open Access

    The importance in early identification of a herpetic endobronchial mass

    by Spandana Narvaneni, Anish Samuel, Rajapriya Manickam, Ashesha Mechineni


  • Open Access

    Emphysematous cholecystitis: A deadly disguise of a common culprit

    by Ashesha Mechineni, Rajapriya Manickam, Balraj Singh

    Emphysematous cholecystitis is a critical differential diagnosis for physicians to consider when evaluating patients with acute abdomen. Patients who are unable to undergo emergency surgery can benefit from percutaneous cholecystostomy.


  • CARDIAC ARREST AND CLINICAL OUTCOMES IN COVID 19 PATIENTS : A SINGLE CENTER EXPERIENCE

    by Ashesha Mechineni, Anish Samuel, Rajapriya Manickam


  • Open Access

    COVID-19 and bleeding at unusual locations: Report of four cases

    by Balraj Singh, Ashesha Mechineni, Parminder Kaur, Ro-Jay Reid, Michael Maroules


  • Open Access

    A Rare Presentation of a Rare Case: Acute Respiratory Failure in Swyer-James-Macleod Syndrome

    by Ashesha Mechineni, Balraj Singh, Rajapriya Manickam

    Swyer-James-Macleod syndrome (SJMS) is a rare clinical entity acquired during childhood due to a respiratory infection leading to bronchiolitis obliterans. This inciting event is hypothesized to cause structural and functional changes of the developing alveoli, terminal bronchioles, and the corresponding pulmonary vasculature, resulting in emphysematous changes and a matched ventilation-perfusion defect. We present a 67-year-old male patient with hypercapnic respiratory failure requiring invasive mechanical ventilation, who had typical features of SJMS undiagnosed before this admission. He was extubated successfully, discharged home, and continues to be stable at a 90-day follow-up period. This marks one of the rare accounts where a patient with SJMS was given ventilatory support emergently, and one of the oldest patients reported. SJMS is under-reported due to its indolent clinical course and misdiagnosed as some other pulmonary abnormality. The clinical course progression and prognosis are unclear and variable in many affected patients due to this condition's rarity.


  • Open Access

    Emphysematous cholecystitis: A deadly disguise of a common culprit.

    by Ashesha Mechineni, Balraj Singh, Rajapriya Manickam

    Emphysematous cholecystitis is caused by gas-forming micro-organisms, primarily in patients with immunosuppression and diabetes mellitus. It leads to a signature radiological finding with air in gall bladder wall as described in this report. Clinicians should be aware of this critical differential diagnosis.